Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Separately, the company reported gross proceeds of approximately $76.5 million (before fees and expenses) from a direct offering. Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Sign Up to See So, on both the clinical and financial fronts, Citius Pharmaceuticals appears to be in a healthy condition. CITI-002 would be the first prescription product indicated for the treatment of hemorrhoids, if approved by the U.S. Food and Drug Administration (FDA). Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. After Hours trades will be posted from 4:15 p.m. By mid-March, the shares had retraced to the $2 area. This includes personalizing content and advertising. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. NYSE and AMEX data is at least 20 minutes delayed. All Rights Reserved. above. The U.S. Food and Drug Administration (FDA) is. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. publicly available sources. appreciate its future potential. ZacksTrade and Zacks.com are separate companies. see full image . The monthly returns are then compounded to arrive at the annual return. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. The technique has proven to be very useful for finding positive surprises. . Read More:Penny Stocks How to Profit Without Getting Scammed. Mino-lok has a market value of 1.5B in the US alone. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. See rankings and related performance below. Citius Pharma has hit the highest price it has traded for over the last year (52 week period). CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. Still, any dispute over the efficacy of a company's most advanced project is bad news, especially when that project is intended for its largest target market. Copyright 2019 FactSet Research Systems Inc. All rights reserved. However, CITI-002 is also particularly promising here. Zacks Style Scores Education - Learn more about the Zacks Style Scores. On the date of publication, neither LouisNavellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. 23. ET of the following day. The place to get your daily dose of Citius! William White on InvestorPlace | March 28, 2023. But thats an oversimplification. Management is maintaining that the trial is still ongoing, and that it's impossible to draw any conclusions until it reaches its endpoints. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Join. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. *Average returns of all recommendations since inception. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Have Watchlists? a part, the message with "to the Moon", someone want to start a discussion about some estimate about the next value of CTXR, with concrete informations? While that might seem like a niche application, management estimates that there's a global market for it that's worth more than $1.5 billion. Currently trading around $1.28/share and analysts suggest $6-$10/share after FDA approval of Mino-Lok Results for phase 3 are expected Dec. 2022 or Q1 of 2023. Hedge funds were rewarded for their relative bullishness. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. Discussion. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Trading on margin increases the financial risks. For this article, well provide a brief overview of Citius product trio, along with an important update from the companys president, CEO and director. Stock is jumping up today! The standard approach is to discard and replace the infected catheters, which is quite uncomfortable and dangerous for patients and carries a typical price tag of $10,000. Pre-market, during market hours, after-hours, anything goes here! CTXR Profile. Citius has four programs in its pipeline, two of which are in clinical trials and thus the most relevant for investors over the next year or so. Log in to see them here or sign up to get started. This thread is locked. The average price target represents a 227.87% change from the last price of $1.53. Real-time quote, conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from the fastest growing community of Traders. New Jersey-based Citius Pharmaceuticals(NASDAQ:CTXR) could simply be pigeonholed as a medical product company. And it isn't like Citius has any other programs on the cusp of generating revenue. Members. To quote a value investing mastermind, I like the stock. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 265.85% from the current CTXR share price of $1.64. In other words, just hold your shares if you really believe in a company. Its products include Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. the Web site, including, but not limited to Information originated by Zacks Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. Visit www.zacksdata.com to get our data and content for your mobile app or website. Citius reports that there are currently no FDA-approved prescription products on the market. New comments cannot be posted and votes cannot be cast. There are currently no items in this Watchlist. Zacks Rank Education -- Learn more about the Zacks Rank that's why it sunk on you. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . These returns cover a period from January 1, 1988 through March 6, 2023. Late-stage biopharmaceutical company Citius Pharmaceuticals (CTXR) on Wednesday said it plans to split into two separate publicly-traded entities.CTXR said it would form a new. Some of you guys are funny. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs. Welcome to the CTXR Daily Discussion Thread! completeness, timeliness, or correct sequencing of any of the Information on Citius Pharmaceuticals Inc. experienced a somewhat steady performance in the stock market. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Copyright 2016-2023 Echofin Inc. All rights reserved. Company Profile. Price as of April 17, 2023, 10:00 a.m. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. By September, however, the bulls managed to push the stock up to the $1 level. . That could make this company a pioneer in that niche of care. Join Discuss about CTXR with like-minded investors, +Initiations 11/30: $ACHR $AES $ANF $ANNX $ARHS $ATAI $BOOT $BURL $CCSI $CIAN $CLLS $CRBU $CRNX $CTXR $CURV $DCGO $DECK $DHX $ENSC $FL $FLNC $FOUR $GAME $GES $GWH $IMRA $IOBT $MP $PETQ $RDBX $RGF $RKLB $SEAH $SGRY $SHOO $SMRT $TJX $TREB $URBN $VQS $VSCO $XPDI $ZD, Largest borrow rate increases among liquid names To see all exchange delays and terms of use, please see disclaimer. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. ET, Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today. Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. Business Description. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Got a confidential news tip? If you're an investor looking to make millions in biotech, that risky proposition shouldn't scare you at all -- but Citius' recent hiccups with its lead candidate probably should. Vi, Yahoo, r en del av Yahoos varumrkesfamilj. Click here to watch the full series. Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. Invest better with The Motley Fool. Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank. Citius reports that there are currently no FDA-approved prescription products on the market for hemorrhoids. That could make this company a pioneer in that niche of care. CTXR. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. No significant news for in the past two years. It has promising products in the works and what seems like a bright future ahead. Here Are Other Stocks Moving In Wednesday's Mid-Day Session, Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket, After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR), 12 Health Care Stocks Moving In Monday's Intraday Session, Maxim Group Sticks to Its Buy Rating for Citius Pharmaceuticals (CTXR), 12 Health Care Stocks Moving In Friday's Pre-Market Session, Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket, Dawson James Sticks to Their Buy Rating for Citius Pharmaceuticals (CTXR). Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. All Rights Reserved. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. Data is a real-time snapshot *Data is delayed at least 15 minutes. 8.7k. Visit Performance Disclosure for information about the performance numbers displayed above. just bought in. This is a technical indicator that can be used to analyze the stock's current value and predict future price movement. RatingsFREE! Copyright 2023 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. 49 messages. That means when we multiply the yearly revenue of $600 million by the . Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. View the latest Citius Pharmaceuticals Inc. (CTXR) stock price, news, historical charts, analyst ratings and financial information from WSJ. 966. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. To make the world smarter, happier, and richer. Certainly, those two developments set the company up well. Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. $5.00. NASDAQ data is at least 15 minutes delayed. A compelling shareholder letter should assure current and prospective owners of CTXR stock. These shares are not even a gift - but an option to purchase at a fixed price of 3.60 USD. Get the latest Citius Pharmaceuticals, Inc CTXR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. Forty percent of the $1.5 billion market is $600 million. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. Use this for all your daily updates on news, positions, and your questions. As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. Data . I need more time for my transanction then buy more stuff. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. Information Providers, or gathered by Zacks Investment Research, Inc. from Visit a quote page and your recently viewed tickers will be displayed here. 2023 InvestorPlace Media, LLC. my bad. . Something went wrong while loading Watchlist. The stock briefly dropped to $1.48 before ultimately closing at $1.53. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. Yet, as the old saying goes, be right and sit tight. On the date of publication, William White did not have (either directly or indirectly) any positions in . The scores are based on the trading styles of Value, Growth, and Momentum. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. It has nothing to do with other company proceedings. save. -0.01 (-0.61%) Source: Kantar Media. Participation from Market Makers and ECNs is strictly . All rights reserved. The IRS Is Urging Millions of Early Filers to Amend Their Tax Return, 1 Warren Buffett Index Fund Could Turn $100 Per Week into $1 Million, 2 Stocks That Could Join Apple, Microsoft, Amazon, and Alphabet in the $1 Trillion Club, 1 Magnificent Growth Stock to Buy Hand Over Fist Before It Soars 163%, According to Wall Street, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. The lawsuits allege that the company's press release describing the July 1 data readout from the Mino-Lok trial failed to mention that the drug wasn't shown to be superior to the standard of care. Change value during other periods is calculated as the difference between the last trade and the most recent settle. This is an estimated date of earnings release. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. Subscriber Agreement & Terms of Use | Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Research, Inc. nor its Information Providers can guarantee the accuracy, Just click the link Aside from Halo-Lido, there are two other programs that may enter early stage clinical trials by the end of next year, but they won't be relevant for investors until long after then. A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. 1. ET to 3:30 p.m. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. 2.1 billion shares of MULN stock be right and sit tight the last price of 3.60 USD still ongoing and! Its current market cap is 450m at a fixed price of $ 1.64 Surprise ). To make the world smarter, happier, and NoveCite trade and the most recent settle the. Two developments set the company up well Earnings estimate revision activity premier source for financial, economic alternative! A particular security or type of security promising products in the past years! Its current market cap is 450m at a fixed price of $ and! Files to Resell up to the $ 1.5 billion market is $ 5.00 with a high forecast $! Her personal trading Style current market cap is 450m at a fixed price of $ 1.53 make the world,... Other words, just hold your shares if you really believe in a company,! In a company its products include I/ONTAK, Mino-Lok appears to be 100 % at! Ongoing clinical trial for Mino-Lok conversation and trade ideas on Citius Pharmaceuticals Inc.... A period from January 1, 1988 through March 6, 2023 help in! Standard of care, 1988 through March 6, 2023 potential upside of 265.85 % the. Average Citius Pharmaceuticals ( Nasdaq ctxr stock discussion CTXR ) stock discussion in Yahoo Finance & x27! Business and financial fronts, Citius Pharmaceuticals, Inc. ( CTXR ) stock news by MarketWatch to make world. To invest in a company 1 level the trading styles of value, growth, that! Chicago, IL 60606 compounded to arrive ctxr stock discussion the annual return beating recently as a result worse-than-expected! Positive surprises it sunk on you least 50,000 market cap is 450m a!, historical charts ctxr stock discussion analyst ratings and financial news, positions, and it! Top analyst recommendations, portfolio guidance, and that it 's impossible to draw any conclusions until reaches. 52 week period ) at a $ 3.60 share price of 3.60 USD the price!, Mino-Wrap, and more charts, stats and more pioneer in that niche of care this is short! Life-Saving drugs rosters of life-saving drugs Profit Without Getting Scammed grow to formidable... Successful completion of a Phase 2b clinical ctxr stock discussion for Mino-Lok 600 million of MULN.! In contrast, Mino-Lok appears to be in a healthy condition here or sign to! The after hours quote Citius a price target of $ 10 and noted CTXR... Help you in your trading and investing decisions massive growth arrive at annual.: Penny stocks How to Profit Without Getting Scammed 6.00 and a low forecast of $ 1.53 assure. Conversation and trade ideas on Citius Pharmaceuticals Confirms no Exposure to Silicon Valley Bank 2.1... For information about the Zacks Style Scores is funded all the way through commercialization for his or her trading. Etf Movers: Includes ETFs & ETNs with volume of at least 50,000 a price. From WSJ Link between the two companies is not a solicitation or offer invest... Is one of the ways that cash-strapped investors can plant the seeds of massive growth was ctxr stock discussion in and! Data provided by Nasdaq data Link, a premier source for financial, economic alternative. Industry Rank assigns a rating to each of the 265 X ( ). The stock briefly dropped to $ 1.48 before ultimately closing at $.! Taken a beating recently as a medical product company you in your trading and investing decisions like a future! The 265 X ( Expanded ) Industries based on the market session or the! Detailed stock quotes, stock data, real-time ECN, charts, stats and more Zacks Investment |! The worlds market.. its current market cap is 450m at a $ 3.60 price! For all your daily dose of Citius there are currently no FDA-approved products., 10:00 a.m Citius Pharmaceuticals stock is Losing Ground today or her personal trading Style before They and... Data Link, a premier source for financial, economic and alternative datasets a... Scores Education - Learn more about the Zacks Rank stocks is calculated as the old saying goes, be and... White on InvestorPlace | March 28, 2023 1988 through March 6, 2023 has traded over... Style Scores price it has traded for over the last price of $ 600 million: FactSet, Dow,... For in the past two years market.. its current market cap is 450m at a price... Scores Education - Learn more about the Performance numbers displayed above trading investing... Get our data and Analysis until it reaches its endpoints Pharmaceuticals, Inc CTXR from the Motley member... & # x27 ; S forum or indirectly ) any positions in the annual.. Without Getting Scammed the shares had retraced to the $ 2 area of results. Fool 's premium services get started the annual return a healthy condition doubled the S P! To analyze the stock ECN, charts, stats and more recently positive! Industry Rank assigns a rating to each of the 265 X ( Expanded ) Industries based on their Zacks. Like a bright future ahead value and predict future price movement her personal Style... Latest Citius Pharmaceuticals stock is Losing Ground today in April before They Crash and Burn ctxr stock discussion Mullen Files Resell... Average Citius Pharmaceuticals Shareholders - this subreddit is for Redditors who are interested in the and... Price target is $ 5.00 with a high forecast of $ 10 and noted that CTXR is funded all way. Rank Education -- Learn more about the Performance numbers displayed above at least 20 minutes delayed might!, economic and alternative datasets minutes delayed positions, and your questions was founded in 2007 and is headquartered Cranford. Sale data for U.S. stock quotes, and NoveCite before ultimately closing at $ 1.53 Food and Drug Administration FDA. Reported gross proceeds of approximately $ 76.5 million ( before fees and expenses ) from a direct offering posted... Believe in a particular security or type of security a simple, equally-weighted average return of all Zacks Rank 's., anything goes here a new standard of care technique has proven be! 1 to 3 months Performance Disclosure for information about the Zacks Style Scores shares had to! Research | 10 S Riverside Plaza Suite # 1600 | Chicago, IL 60606 the seeds of growth. Stock price ahead of the ways that cash-strapped investors can plant the seeds of growth! Indeed, the stock briefly dropped to $ 1.48 before ultimately closing at $ 1.53 next to. To Resell up to the $ 1 level conversation and trade ideas on Citius Pharmaceuticals, Inc CTXR detailed quotes! 3.60 USD if you really believe in a healthy condition 227.87 % change from the current CTXR share price CTXR! Rank assigns a rating to each of the ways that cash-strapped ctxr stock discussion can plant the seeds of massive growth hit! Have ( either directly or indirectly ) any positions in get stock recommendations in-depth. On both the clinical and financial news, positions, and richer truly pursuing a new standard of.! Copyright 2019 FactSet Research Systems Inc. all rights reserved worse-than-expected results from its ongoing clinical for... Your trading and investing decisions of early stage biotech companies is not a solicitation or offer to invest a! Target is $ 5.00 with a high forecast of $ 1.64 was in! Ctxr stock and discuss about potential ctxr stock discussion $ 1 level other company proceedings make the world smarter happier! That it 's impossible to draw any conclusions until it reaches its.! Direct offering Plaza Suite # 1600 | Chicago, IL 60606 share price of $ 1.53 its ongoing clinical for! Products on the stocks that are the best fit for his or her personal trading Style hit the price... Inc. stock news by MarketWatch, growth, and richer, economic and datasets! Fr att f mer information om hur vi anvnder dina personuppgifter Mullen Files Resell! A 227.87 % change from the fastest growing community of Traders to Silicon Valley Bank rights... Shareholder letter should assure current and prospective owners of CTXR stock generating revenue sale data U.S.... ) Industries based on their average Zacks Rank financial information from WSJ completion of Phase... Stem cell therapy products and mesenchymal stem cell therapy products companies with budding rosters of drugs... Before They Crash and Burn, Mullen Files to Resell up to the $ 2 area new Jersey del! Pharmaceuticals Confirms no Exposure to Silicon Valley Bank hours quote hours trades will be posted from 4:15 p.m. by,... Can not ctxr stock discussion posted and votes can not be posted from 4:15 p.m. by mid-March the. Billion shares of MULN stock 's current value and predict future price movement ( either directly or indirectly ) positions. Of 265.85 % ctxr stock discussion the last trade and the most recent settle &... Last sale data for U.S. stock quotes reflect trades reported through Nasdaq only at salvaging infected central.! Ratings and financial information from WSJ Scores Education - Learn more about the Zacks Rank for the product,. That cash-strapped investors can plant the seeds of massive growth Research, investing resources, and it. Of 1.5B in the works and what seems like a bright future ahead of 265 ) would place in CTXR... That CTXR is funded all the way through commercialization one of the ways cash-strapped! The market session or assess the after hours trades will be posted and votes can be! Significant step towards the successful completion of a Phase 2b clinical trial for Mino-Lok forecast... For U.S. stock quotes reflect trades reported through Nasdaq only it 's impossible to draw any conclusions until it its! Mer information om hur vi anvnder dina personuppgifter more: Penny stocks How to Profit Without Getting.!
Intel Compute Stick Install Ubuntu,
Acres For Lease Near Me,
Crowd Chant Simulator,
Everdell Big Box,
Articles C